Rentosertib just cleared a threshold no AI-discovered drug has reached before: 320 patients, 47 sites, 52 weeks of treatment in a randomized, double-blind, placebo-controlled Phase III. Insilico Medicine dosed the first participant in GENESIS-IPF-3 at Peking Union Medical College Hospital in China, with Shanghai Pulmonary Hospital enrolling its own first patient the same day. The trial’s primary endpoint is annual rate of decline in forced vital capacity over those 52 weeks, a direct test of whether the drug’s Phase IIa lung-function signal holds at scale and duration.
What makes the trial design worth watching is the target itself. TNIK had no prior connection to fibrosis before Insilico’s generative AI identified it, and the Phase IIa data published in Nature Medicine in 2025 showed a dose-dependent efficacy trend that justified the progression. Pirfenidone and nintedanib, the two FDA-approved antifibrotics for IPF both cleared in October 2014, slow progression through different mechanisms; rentosertib targets a pathway neither of them touches, which is the clinical rationale for running a full Phase III rather than positioning around existing options. The FDA granted rentosertib Orphan Drug Designation in February 2023, and the drug remains investigational with no regulatory approval anywhere.
The timeline question is concrete: lead investigator Professor Zuojun Xu put the span from Phase III initiation to potential approval at three to four years under favorable conditions. That estimate, paired with the 52-week treatment window across 47 Chinese centers, means primary readout data is unlikely before late 2027 at the earliest. A 2026 Nature Biotechnology study reporting consistent reductions in biological age across six independent aging clocks adds a secondary signal Insilico will almost certainly use to support label expansion discussions if the FVC endpoint holds, though that data remains observational for now.
Insilico's financial position changes the usual risk calculus for a company at this stage. The company reported $106 million in revenue for the first half of 2026, a 287% year-over-year increase, and its first profitable half-year since its December 2025 HKEX listing, with adjusted net profit exceeding $51 million. That profitability comes from out-licensing and co-development deals totaling roughly $7.3 billion in announced contract value this year alone. A company funding Phase III from licensing revenue rather than equity dilution can sustain enrollment pressure differently, and whether that commercial model survives the three-to-four-year runway to approval is the number to track alongside the FVC slope.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
